A Study on the Effects of Pediococcus Acidilactici on the Improvement of Atopic Dermatitis
- Conditions
- Diseases of the skin and subcutaneous tissue
- Registration Number
- KCT0008444
- Lead Sponsor
- Wonkwang University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
1) A person who is 19 years of age or older and under 65 years of age
2) A person whose symptoms of atopic dermatitis have persisted for at least 6 months as of visit 1
3) A person whose SCORAD (SCORing Atopic Dermatitis) score corresponds to 25-50 points (Moderate) at the time of Visit 1 and Visit 2
4) A person who agrees to participate in this study and prepares an informed consent form prior to the commencement of the study
1) A person currently being treated for severe cardiovascular, immune, respiratory, gastrointestinal/hepatic and biliary systems, kidney and urology, nervous, musculoskeletal, infectious diseases and malignant tumors
2) In addition to atopic dermatitis, a person who has a skin disease that inhibits the accurate evaluation of the results of atopic dermatitis, such as irritant contact dermatitis, allergic contact dermatitis, infection (ohms, etc.) or psoriasis
3) Those with skin or skin infections (bacteria, viruses, fungi) requiring systemic treatment within two weeks of visit (excluding localized water lions with fewer than 20 lesions and viral warts)
4) A person who has systemic diseases such as immunodeficiency, autoimmune disease, cancer, etc
5) Persons deemed to influence this study due to other medical (liver disease, renal failure, etc.) and psychotic and neuropathic causes
6) A person who has an unstable and uncontrolled chronic medical disease (high blood pressure, diabetes, etc.), psychotic and neuropathic disease
7) an alcoholic or drug-dependent person
8) A person who has received the following drugs or treatments before visiting
A. A person who has administered systemic antibiotics, steroids, or immunosuppressants within 4 weeks of visit 1
B. A person who has consumed herbal medicine, health functional foods, and probiotics products related to atopic dermatitis within 4 weeks of visiting 1
C. A person who has received phototherapy within 4 weeks of visiting 1
D. Those who have been treated with topical steroids, topical immunosuppressants, oral antihistamines and topical antibiotics/antifungal agents within two weeks of visit 1 (except when inhaled steroids are used for asthma treatment)
9) A person who has a history of infectious bowel disease within two weeks of visiting 1
10) Those whose creatine is more than twice the normal upper limit of the implementing agency
11) A person whose AST (GOT) or ALT (GPT) is more than three times the upper limit of the institution
12) A person who is pregnant, lactating or planning to conceive during the period of this study
13) A person who is sensitive or allergic to food ingredients for this study
14) A person who has participated in another interventional study within three months of the commencement of this study or has plans to participate in another interventional study since the commencement of this study
15) A person who judges that the tester is inappropriate for other reasons
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SCORing of Atopic Dermatitis index
- Secondary Outcome Measures
Name Time Method Investigator’s Global Assessment;NRS(Numeral Rating Scale);Dermatology Life Quality Index;Transdermal moisture loss, skin moisture content, skin surface melanin index, and skin acidity;Immune-related blood indicators;a stool test